Huan Qiu Wang Zi Xun·2026-01-13 04:13Core Insights - Nvidia and Eli Lilly have announced the establishment of the first artificial intelligence joint innovation lab aimed at addressing long-standing challenges in the pharmaceutical industry and transforming drug development [1][4] Funding and Operations - The two companies plan to invest up to $1 billion over the next five years to ensure the lab's efficient operation, focusing on talent recruitment, infrastructure development, and computational resource allocation [4] - The lab will be located in the San Francisco Bay Area, where experts from Eli Lilly in biology, science, and medicine will collaborate with Nvidia's top AI model builders and engineers [4] Technological Advancements - The lab will utilize Nvidia's BioNeMo platform to generate large-scale data and build AI models, thereby accelerating the drug development process [4] - Nvidia's CEO, Jensen Huang, emphasized that AI is reshaping various industries, with a profound impact on life sciences, and that the collaboration aims to create a new blueprint for drug development [4]